Oxaprozin (Daypro)

An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.

Also Known As:

Networked: 59 relevant articles (8 outcomes, 22 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Bananej, Maryam: 2 articles (06/2022 - 04/2022)
2.	Khatami, Parisa: 2 articles (06/2022 - 04/2022)
3.	Khosravi, Maryam: 2 articles (06/2022 - 04/2022)
4.	Mirazi, Naser: 2 articles (06/2022 - 04/2022)
5.	Atmakuri, Lakshmana R: 1 article (02/2018)
6.	Mandava Venkata, Basaveswara R: 1 article (02/2018)
7.	Pachava, Vengalrao: 1 article (02/2018)
8.	Peesa, Jaya P: 1 article (02/2018)
9.	Rasheed, Arun: 1 article (02/2018)
10.	Yalavarthi, Prasanna R: 1 article (02/2018)

Related Diseases

1.	Pain (Aches) 01/01/1999 - "HRQOL was measured by the Medical Outcomes Study Short-Form-36 Health Survey (1-week recall period) at baseline and weeks 2 and 6. Data from the 2 trials were combined to assess differences across the 4 groups in 8 domains and 2 summary scores at baseline, and changes in HRQOL scores at weeks 2 and 6. At week 2, the oxaprozin group showed significantly greater improvement than the placebo group in role physical, vitality, and mental component summary (MCS) scores (P < 0.05), and in physical functioning, bodily pain, social functioning, and physical component summary (PCS) scores (P < 0.01). " 01/01/1999 - "At week 6, oxaprozin treatment resulted in significantly greater improvement than placebo in physical functioning, role physical, and bodily pain (P < 0.05); social functioning, role emotional, and mental health (P < 0.01); and vitality and MCS score (P < 0.001). " 03/01/1988 - "Oxaprozin-treated patients showed significant improvement in spontaneous pain of the vertebral spine and in morning stiffness after 6 weeks' treatment. " 08/01/2004 - "Oxaprozin: kinetic and dynamic profile in the treatment of pain." 01/01/1984 - "Assessments made on entry and after 4 and 8 weeks of treatment showed that in the oxaprozin group there were significant mean decreases, indicating improvement in patient's condition, with respect to observer's opinion, patient's opinion, pain intensity and activity impairment at both on-therapy visits. "
2.	Osteoarthritis 05/01/1992 - "Its spectrum of anti-inflammatory activity has been demonstrated in both in vitro and in vivo models.1 The majority of published clinical trials have focused on the use of oxaprozin (from Searle) in the treatment of osteoarthritis and rheumatoid arthritis." 04/01/1998 - "The present study should elucidate the efficacy, patient acceptability, and side effect profiles of Oxaprozin and Diclofenac retard when given to patients with active primary osteoarthrosis. " 01/01/1996 - "This 6-week, multicenter, double-masked, placebo-controlled study compared the efficacy, tolerability, and safety of the recommended starting dose of oxaprozin (1200 mg/d) and a 1500-mg/d dose of nabumetone in the treatment of patients with moderate-to-severe osteoarthritis (OA) of the knee. " 07/01/1995 - "This multicenter, 6-week, double-blind, placebo-controlled, parallel-group study compared the efficacy and safety of oxaprozin 1200 mg once daily with that of nabumetone 1000 mg once daily in patients with moderate-to-severe osteoarthritis (OA) of the knee. " 01/01/1984 - "A double-blind, parallel trial of oxaprozin versus naproxen in the treatment of osteoarthritis."
3.	Tendinopathy (Tendonitis) 01/01/1983 - "The results of this study indicate that oxaprozin is as effective and safe as phenylbutazone and superior to placebo in the treatment of patients with acute tendinitis and bursitis." 01/01/1983 - "The effects of 1,200 mg of oxaprozin once daily, 100 mg of phenylbutazone four times daily, and placebo were compared in the treatment of 125 patients with acute tendinitis and bursitis in a seven-day double-blind study at six clinical sites. " 01/01/1983 - "A multicenter, double-blind comparison of oxaprozin, phenylbutazone, and placebo therapy in patients with tendinitis and bursitis."
4.	Bursitis (Adhesive Capsulitis) 01/01/1983 - "The results of this study indicate that oxaprozin is as effective and safe as phenylbutazone and superior to placebo in the treatment of patients with acute tendinitis and bursitis." 01/01/1983 - "The effects of 1,200 mg of oxaprozin once daily, 100 mg of phenylbutazone four times daily, and placebo were compared in the treatment of 125 patients with acute tendinitis and bursitis in a seven-day double-blind study at six clinical sites. " 01/01/1983 - "A multicenter, double-blind comparison of oxaprozin, phenylbutazone, and placebo therapy in patients with tendinitis and bursitis."
5.	Inflammation (Inflammations) 05/01/1979 - "The development of oxaprozin provided an opportunity to evaluate the control of inflammation in rheumatoid arthritis by a drug that can be administered once daily. " 07/01/1984 - "[Clinical evaluation of oxaprozin in the treatment of acute upper respiratory tract inflammations--a double-blind comparative study using ibuprofen as the control drug]." 02/01/2002 - "Oxaprozin eye drops significantly reduced the signs of ocular inflammation elicited by sodium arachidonate on conjunctiva and iris. " 08/01/2004 - "Oxaprozin (4,5-diphenyl-2-oxazolepropionic acid) is a non-steroidal anti-inflammatory drug (NSAID) which is effective in models of inflammation, pain and pyrexia. " 02/01/2002 - "The effects of eye drops containing a propionic acid derivative (oxaprozin) at 0.1% concentration on ocular inflammation produced by sodium arachidonate in the rabbit's eye were evaluated. "

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	Diclofenac (SR 38)
3.	Nabumetone
4.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
5.	Phenylbutazone (Butazolidin)
6.	Naproxen (Naprosyn)
7.	Ibuprofen (Motrin)
8.	Sulindac (Copal)
9.	Anti-Inflammatory Agents (Anti-Inflammatories)
10.	Tablets

Related Therapies and Procedures

1.	Therapeutics
2.	Pain Management
3.	Oral Surgery (Maxillofacial Surgery)